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Introduction and study objective
Fotemustine (FTM) is a third-generation nitrosourea.
Recently, several groups have studied the use of FTM in
high grade glioma (HGG) patients recurring after standard
radiotherapy (RT) and temozolomide (TMZ) treatment [1–
3]. With the FTM standard schedule (dose of 100 mg/sqm/
week for 3 consecutive weeks as an induction treatment,
followed by 100 mg/sqm every 3 weeks, after a 5-week
rest, as maintenance treatment) myelosuppression repre-
sents the most common adverse event, mainly occurring
during the induction phase of treatment. In a modified
schedule proposed by Addeo et al. [4], FTM was admin-
istered at a dose of 80 mg/sqm every 2 weeks for five
consecutive administrations as the induction phase and
every 4 weeks at 80 mg/sqm as the maintenance phase.
Accordingly, in a prospective single-institution study, we
addressed the toxicity of a modified FTM schedule in
patients with HGG at 1st and 2nd progression after failure
of RT and TMZ.
Methods and statistical analysis
Between January 2011 and October 2012, 97 consecutive
patients with a diagnosis of HGG at first or second recur-
rence after standard treatment were treated with an out-
patient regimen with a non conventional schedule of FT as
proposed by Addeo et al. The protocol was approved by
our Institutional Review Board, and each patient provided
written informed consent before initiation of treatment. In
this setting, clinical, radiological and laboratory data of all
patients treated were collected. In particular complete
blood count (CBC) with differential, biochemistry panel
(BUN, creatinine, liver enzymes, glucose), erythrocyte
sedimentation rate (VES), C-reactive protein (CRP) and
CD4 count were assessed every cycle. Toxicity was eval-
uated according to the Common Terminology Criteria for
Adverse Events (CTCAE; version 3.0). Median progres-
sion-free survival at 6 months (PFS-6) and median overall
survival (m-OS) were calculated for the whole group of
patients, as secondary study endpoints. Descriptive statis-
tics were used to summarize relevant study information.
PFS and OS were calculated by the Kaplan–Meier method.
Results
Clinical characteristics and toxicity profile of the 97 patients
(59 male and 38 female) included in the study are summa-
rized in Table 1 and 2. Overall, patients received a total of
431 chemotherapy cycles: the median number of cycles was
5 (range, 2–13). Only one patient interrupted chemotherapy
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due to hematological grade IV toxicity. In all patients, CD4
? lymphocytes counts were monitored: 18.5 % of patients
developed grade 3–4 CD4 ? lymphopenia (\200 cell/lL).
All patients with grade 3/4 CD4 ? lymphopenia received
prophylactic cotrimoxazol. None of these patients developed
Pneumocystis carinii pneumonia. Moreover, no death was
considered to be closely related to chemotherapy toxicity.
Major non hematological toxicities (grade 3–4) concerned
mainly hepatic enzymes, particularly GGT that increased in
5.5 % of cases Minor toxicities (grade I–II) were anemia
(42.1 %), thrombocytopenia (15.1 %), leukopenia (9.2 %),
AST/ALT increase (approximately 40 %), worsening of
renal function (2.8 %), and gastrointestinal toxicity (6.2 %).
Infections were observed in 9 cases (2 pulmonary, 2 urinary
trait, 5 other) and deep venous thrombosis in 7 cases.
Discussion and conclusions
The management of patients with recurrent HGG is par-
ticularly challenging due to the lack of a standard of care.
Significant evidence exists from preclinical and clinical
studies for the activity of FTM particularly in recurrent
malignant glioma. In the FTM standard regimen, hemato-
logical toxicity represents the most important side effect,
with grade 3–4 toxicities in nearly 40 % of patients. Thus,
to improve the safety of FTM use, several groups have
reported experiences with alternative schedules [1, 2]; in
particular Addeo et al. reported results of an alternative
FTM schedule where the total FTM dose at the end of
induction was maintained but with a different fractionation
[4]. In 2008, our group reported the results of a combi-
nation schedule of FTM with procarbazine (PCB) in
recurrent malignant glioma patients [5]. In that study, we
used PCB at a dose of 450 mg/day on days 1–3 and FTM
at a dose of 110 mg/sqm in a single monthly administra-
tion on day 3. A limitation of our combination schedule
was most likely the abolition of the induction phase,
consequently reducing the total amount of FTM adminis-
tered. Thus, because we are now convinced of the crucial
role of the induction phase in the FTM treatment, we used
an alternative schedule in the present paper on recurrent
glioma patients that would ensure an acceptable toxicity
profile. The treatment was very well tolerated, the analysis
on collected data showed a good safety profile with only
few grade 3–4 toxicities. Only in one case, after three
infusions of FTM, a young girl had severe hematological
toxicities that required treatment discontinuation. Only two
fatal pulmonary embolisms were recorded, although they
were not closely correlated with chemotherapy but with the
tumor itself.
In our series of patients the 6-PFS was 38.2 %
(± 0.0695); the median OS was 30 weeks, with a OS-6 of
56 % and a OS-12 of 18 %. Even if this is a prospective
study with a limited number of patients, and our patient
population is heterogeneous (including grade III and grade
IV gliomas) our results in term of efficacy are quite com-
parable as 6-PFS and responses to other studies on standard
FT schedule; however at the moment whether it could be
more effective than the conventional regimen remains
unclear, but limited toxicity compared to conventional
schedule makes it safe to use in clinical practice.
In conclusion, although the present study utilized a
limited number of patients, it confirms the safety of the
alternative FTM schedule proposed by Addeo et al.
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Table 1 Patient’s characteristics
Patients n = 97
Clinical characteristics
Median age, years (range) 56.5 (20–72)




Grade III gliomas 21






Second line chemotherapy (number of patients) 83
Third line chemotherapy (number of patients) 14
Total cycles administered 431
Median cycles received, number (range) 5 (2–13)
Induction phase completed (number of patients) 20
All cycles completed (number of patients) 14
Survival data for the whole group of patients
6 months -PFS 38, 2 %
6 months-OS 56 %
12 months -OS 18 %
Median PFS 16 weeks
Median OS 30 weeks
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Table 2 Summary of chemotherapy related toxicity
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Haematological
Anemia 176 (40.8 %) 6 (1.3 %) – –
Thrombocytopenia 60 (13.9 %) 5 (1.2 %) – 1 (0.3 %)
Leukopenia 29 (6.7 %) 11 (2.5 %) – 1 (0.3 %)
CD4 ? lymphopenia 23 (5.3 %) 98 (22.7 %) 79 (18.3 %) 1 (0.2 %)
Non haematological
Hypertransaminasemia
[AST 35 (8.1 %) 4 (0.9 %) – –
[ALT 107 (24.8 %) 22 (5.1 %) 5 (1.2 %) –
[Gamma GT 89 (20.6 %) 36 (8.3 %) 18 (4.2 %) 6 (1.4 %)
Renal
Creatinine 12 (2.8 %) – – –
Gastrointestinal
Nausea/vomiting 21 (6.2 %) – – –
Other chemotherapy treatment related adverse event Number of cases (%)
Infections 9 (9.2 %)
Pulmonary 2 (2 %)
Urinary trait 2 (2 %)
Other 5 (5.1 %)
Mycosis/parasitosis 12 (12.3 %)
Deep venous thrombosis 7 (7.2 %)
Fatal 2 (2 %)
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